

Genetic heterogeneity of cytogenetically normal AML with mutations of *CEBPA*

Nikola P. Konstandin,¹⁻³ Friederike Pastore,⁴ Tobias Herold,¹⁻³ Annika Dufour,¹ Maja Rothenberg-Thurley,¹ Tanja Hinrichsen,⁵ Bianka Ksienzyk,¹ Sebastian Tschuri,¹⁻³ Stephanie Schneider,¹ Eva Hoster,⁶ Wolfgang E. Berdel,⁷ Bernhard J. Woermann,⁸ Maria C. Sauerland,⁹ Jan Braess,¹⁰ Stefan K. Bohlander,¹¹ Hanns-Georg Klein,⁵ Wolfgang Hiddemann,¹⁻³ Klaus H. Metzeler,¹⁻³ and Karsten Spiekermann¹⁻³

¹Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany; ²German Cancer Research Center, Heidelberg, Germany; ³German Cancer Consortium, Partner Site Munich, Munich, Germany; ⁴Department of Internal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany; ⁵Center for Human Genetics and Laboratory Medicine, Martinsried, Germany; ⁶Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany; ⁷Department of Medicine A—Hematology, Oncology and Pneumology, University of Münster, Münster, Germany; ⁸Division of Hematology, Oncology and Tumor Immunology, Department of Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; ⁹Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany; ¹⁰Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany; and ¹¹Leukaemia & Blood Cancer Research Unit, Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand

Key Points

- bi*CEBPA*-mutated AML is a heterogeneous subentity that consists of at least 2 subgroups with different genetic and clinical features.

Biallelic mutations of the CCAAT/enhancer binding protein α (*CEBPA*) gene define a distinct genetic entity of acute myeloid leukemia (AML) with favorable prognosis. The presence of *GATA2* and *CSF3R* mutations that are specifically associated with this subgroup but not mutated in all samples suggests a genetic heterogeneity of bi*CEBPA*-mutated AML. We characterized the mutational landscape of *CEBPA*-mutated cytogenetically normal AML by targeted amplicon resequencing. We analyzed 48 biallelically mutated *CEBPA* (bi*CEBPA*), 32 monoallelically mutated *CEBPA* (mo*CEBPA*), and 287 wild-type *CEBPA* (wt*CEBPA*) patient samples from German AML Cooperative Group studies or registry. Targeted sequencing of 42 genes revealed that mo*CEBPA* patients had significantly more additional mutations and additional mutated genes than bi*CEBPA* patients. Within the group of bi*CEBPA* patients, we identified 2 genetic subgroups defined by the presence or absence of mutations in chromatin/DNA modifiers (C), cohesin complex (C), and splicing (S) genes: bi*CEBPA*^{CCSpos} (25/48 [52%]) and bi*CEBPA*^{CCSneg} (23/48 [48%]). Equivalent subgroups were identified in 51 bi*CEBPA* patients from the Cancer Genome Project. Patients in the bi*CEBPA*^{CCSpos} group were significantly older and had poorer overall survival and lower complete remission rates following intensive chemotherapy regimens compared with patients in the bi*CEBPA*^{CCSneg} group. Patients with available remission samples from the bi*CEBPA*^{CCSpos} group cleared the bi*CEBPA* mutations, but most had persisting CCS mutations in complete remission, suggesting the presence of a preleukemic clone. In conclusion, CCS mutations define a distinct biological subgroup of bi*CEBPA* AML that might refine prognostic classification of AML. This trial was registered at www.clinicaltrials.gov as #NCT00266136 and NCT01382147.

Introduction

Mutations in the CCAAT/enhancer binding protein α (*CEBPA*) gene are detected in ~10% of patients with cytogenetically normal (CN) acute myeloid leukemia (AML). *CEBPA* mutations can be either biallelic or monoallelic. Most patients with 2 *CEBPA* mutations carry 1 frameshift mutation in the N-terminal part of the




Figure 1. Mutation spectrum of moCEBPA, biCEBPA, and wtCEBPA.

Evaluation of the mutation spectrum of moCEBPA ($n = 32$) and biCEBPA ($n = 48$) patients in comparison with wtCEBPA samples ($n = 287$). Eight of 20 genes with a mutation frequency of $\geq 5\%$ were significantly associated with ≥ 1 groups.

protein and the other one in the bZIP domain, which is located at the C terminus.^{1,2} A single *CEBPA* mutation is most often found at the N terminus. N-terminal frameshift mutations specifically abolish the translation of the full-length (42-kDa) protein of *CEBPA*, leading to the overexpression of a shorter, dominant-negative 30-kDa isoform of *CEBPA*.³ C-terminal in-frame mutations disrupt the homo- and heterodimerization domains and therefore impair the DNA-binding activity of the *CEBPA* protein.^{4,5} Only patients with biallelically mutated *CEBPA* (biCEBPA) have favorable outcomes when compared with other CN-AML patients.^{2,6-12} Because of its unique characteristics, AML with biCEBPA mutations are classified as a distinct entity in the 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.¹⁰ biCEBPA mutations are rarely associated with other prognostic mutations such like internal tandem duplications (ITD) of the *fms*-like tyrosine kinase 3 (*FLT3*) gene, mutations in the tyrosine kinase domain (TKD) of *FLT3*, mutations in nucleophosmin 1 gene (*NPM1*), or partial tandem duplications of the lysine methyltransferase 2A (*KMT2A*) gene. We previously identified a specific association of biCEBPA mutations with mutations in the transcription factor *GATA2* in 39% of cases.¹³ *CSF3R* mutations are described to be also frequently mutated (29%) in biCEBPA patients.¹⁴ In the present study, we aimed to characterize the mutational spectrum of moCEBPA and biCEBPA CN-AML patients. We also analyzed outcome in patients with biCEBPA mutations based on these additional mutations.

Methods

Targeted amplicon resequencing (Agilent Haloplex; target region, ~ 62 kbp) was used to analyze 42 genes and hotspots in 80 *CEBPA* mutated AML patients (32 monoallelically mutated *CEBPA* [moCEBPA] and 48 biCEBPA); 65 of these AML patients (40 biCEBPA and 25 moCEBPA) were enrolled in the German AML Cooperative Group (AML CG) 1999 or 2008 multicenter

Table 1. Characteristics of moCEBPA vs biCEBPA patients

Characteristic	moCEBPA	biCEBPA	P
Age, y			.69
Median	62	57	
Range	16-78	20-84	
Sex			
Female	23 (72)	23 (48)	.04
WBC count, $\times 10^9/L$	31/32	47/48	.47
Median	30	28	
Range	0.4-188	1.3-408.6	
Hemoglobin, g/dL	29/32	44/48	.13
Median	9.1	10	
Range	2.7-13.2	6.4-13.8	
Platelet count, $\times 10^9/L$	28/32	47/48	.09
Median	52	32	
Range	3-291	3-151	
Bone marrow blasts, %	19/32	40/48	.65
Median	85	71	
Range	30-95	20-100	
LDH, U/dL	20/32	36/48	.67
Median	392	479	
Range	152-2666	205-2510	

Data represent number or n (%) of patients, unless otherwise indicated. Bold indicates significant P values.

LDH, lactate dehydrogenase; WBC, white blood cell.

randomized phase 3 trials or in the AMLCG registry. All other patients were treated according to standard intensive induction/postremission protocols. Long-term follow-up data were available for all moCEBPA patients and 45 of 48 biCEBPA patients.

Treatment protocols of the AMLCG 1999 (registered at www.clinicaltrials.gov as #NCT00266136) or AMLCG 2008 (#NCT01382147) trials have been reported previously.^{15,16} Study protocols were approved by the ethics committees of the participating centers. From all patients, written informed consent to the scientific use of surplus samples was obtained in accordance with the Declaration of Helsinki.

Genomic DNA was extracted from bone marrow or peripheral blood samples using QIAcube technology (QIAGEN, Hilden, Germany). 200 ng double-stranded genomic DNA, as quantified by a Qubit Fluorometer 2.0 (Life Technologies, Carlsbad, CA), was used for the target capture reaction from each sample. A custom-design HaloPlex Target Enrichment kit (1-500 kb; Agilent, Boeblingen, Germany) was employed to capture the target regions according to the HaloPlex Target Enrichment System-Fast Protocol Version B. Paired-end sequencing (2×250 bp) was performed on an Illumina MiSeq instrument (Illumina, San Diego, CA). Sequence alignment and variant detection was performed as described previously.¹⁷ A variant allele frequency threshold of 2% was set for mutation detection. *CEBPA* mutations in diagnosis and if available in remission samples were identified using fragment-length analysis with subsequent Sanger sequencing.¹ *FLT3*-ITD status was analyzed via fragment length analysis.¹⁸ *CSF3R* (NM_156039) exons 14-17 were analyzed by Sanger sequencing.¹⁹ Sequence traces were analyzed with Sequencher software (Gene Codes, Ann Arbor, MI). Target regions




Figure 2. Frequency of genetic alterations organized by categories of related genes and genetic groups. The heatmap includes all genes that were mutated in either the moCEBPA (red) or biCEBPA (dark blue) subgroup. biCEBPA patient samples were further separated in 2 biological groups: CCSneg (blue) and CCSpos (green). Patients with a signal ratio of *FLT3-ITD* ≥ 0.5 are marked with an asterisk.

of remission samples were analyzed by sequencing analysis on the Ion PGM system (coverage ~ 1000 -fold).

Differences in patient characteristics were calculated using the Fisher's exact test for categorical variables and Mann-Whitney *U* test for continuous variables. The Fisher's exact test was used to compare pairwise mutation frequencies among the 3 *CEBPA* groups (moCEBPA or biCEBPA and wild-type *CEBPA* [wtCEBPA]) for genes with a mutation frequency $\geq 5\%$ in at least 1 of the *CEBPA* groups. Adjustment for multiple hypothesis testing was performed using the method described by Benjamini and Hochberg.²⁰ To evaluate differences in additional mutated genes or number of additional gene mutations between moCEBPA and biCEBPA patients, we used the Mann-Whitney *U* test. We further characterized the mutation profile of biCEBPA-mutated patients. There is evidence that AML patients with mutations in chromatin modifier and splicing genes have poor outcomes.²¹ We therefore analyzed outcomes depending on presence and absence of chromatin modifiers and splicing genes and added cohesion genes to this group upon its interaction with chromatin. All clinical end points were defined according to generally accepted criteria.²² Overall survival (OS) was calculated from the date of randomization for patients in clinical trials or at the date of first diagnosis for patients in registry until death from any cause. Relapse-free survival (RFS) was determined for responders from the first day of complete remission (CR) until relapse or death from any cause. Estimated probabilities of OS

and RFS were calculated using the Kaplan-Meier method. The log-rank test evaluated statistical differences (*P* value) between survival distributions. Patients who had undergone allogeneic bone marrow transplantation were censored at the time of transplantation. For all tests, $P \leq .05$ was considered significant. Statistical computations were performed using SPSS software version 20.0 (SPSS, Chicago, IL) and the R software package version 3.3.1 (R Foundation for Statistical Computing; www.r-project.org).

Results

Using targeted resequencing, we analyzed a cohort of 80 *CEBPA*-mutated CN-AML patients ($n = 48$ biCEBPA, $n = 32$ moCEBPA) for mutations in 42 genes (supplemental Tables 1 and 2). *CEBPA* and *FLT3-ITD* mutational status was analyzed using conventional techniques (supplemental Tables 3 and 4).

We evaluated the mutational spectrum of our *CEBPA* cohort in comparison with a cohort of 287 wtCEBPA patients.¹⁷ Among the 20 genes with a mutation frequency of $\geq 5\%$, 8 were significantly associated with *CEBPA* mutation status (Figure 1).

We found significantly more *STAG2* (25%; $P = .04$) and *FLT3-TKD1/2* (25%; $P = .01$) mutations in the moCEBPA subgroup than in the biCEBPA group. Most of the TKD mutations in the moCEBPA cohort were subclonal. *GATA2* (35%) and *CSF3R* (10%) mutations were most frequently found in biCEBPA-mutated




Figure 3. Age and CR rate of $\text{biCEBPA}^{\text{CCSpos}}$, $\text{biCEBPA}^{\text{CCSneg}}$, and moCEBPA patients. (A) Age of $\text{biCEBPA}^{\text{CCSneg}}$ (median = 48), $\text{biCEBPA}^{\text{CCSpos}}$ (median = 66), and moCEBPA (median = 62) patients. Scatter dot plot, median with interquartile range. (B) The CR rate was significantly higher in $\text{biCEBPA}^{\text{CCSneg}}$ patients (91% [20/22]) than $\text{biCEBPA}^{\text{CCSpos}}$ (61% [14/23]; $P = .035$) and moCEBPA patients ($P = .027$).

patient samples. In our cohort, *IDH2* and *NPM1* mutations were mutually exclusive of biCEBPA mutations.

DNMT3A was most frequently detected in wtCEBPA (49%) patients. The frequency of *DNMT3A* mutations in wtCEBPA was significantly different from those in biCEBPA (15%; $P < .001$), but not moCEBPA (28%; $P = .07$).

We found a higher frequency of *FLT3*-ITD mutations in moCEBPA (41%; $P = .13$) and wtCEBPA (41%; $P = .02$) patients than biCEBPA patients (21%).

TET2 mutations were significantly more frequent in moCEBPA (44%, $P = .003$) and biCEBPA (42%, $P = .001$) patients than wtCEBPA patients. In our data set, the frequency of *TET2* mutations is much higher than that of other *CEBPA*-mutated AML cohorts.²³ The frequency in our *CEBPA* cohort is also higher when compared with other AML cohorts.^{24,25}

TET2 mutations were located within the conserved region of the gene and are thus likely pathogenic.^{26,27} These data show that *TET2* mutations define a subgroup of *CEBPA*-mutated samples regardless of the *CEBPA* allelic mutation status.

Table 2. Characteristics of $\text{biCEBPA}^{\text{CCSneg}}$ vs $\text{biCEBPA}^{\text{CCSpos}}$ patients

Characteristic	$\text{biCEBPA}^{\text{CCSneg}}$	$\text{biCEBPA}^{\text{CCSpos}}$	<i>P</i>
Age, y			
Median	48	66	.005
Range	20-71	28-84	
Sex			
Female	12 (52)	11 (44)	.77
WBC count, $\times 10^9/\text{L}$			
Median	11.8	30.8	.39
Range	1.3-408.6	1.7-284.4	
Hemoglobin, g/dL			
Median	10.1	9.7	.12
Range	7.9-13.8	6.4-12.1	
Platelet count, $\times 10^9/\text{L}$			
Median	28	35	.89
Range	3-151	10-120	
Bone marrow blasts, %			
Median	66	75	.58
Range	20-97	31-100	
LDH, U/dL			
Median	427	561	.14
Range	205-2510	229-1660	

Data represent number or n (%) of patients, unless otherwise indicated. Bold indicates significant *P* values.

Next, we compared both *CEBPA* subgroups. With the exception of sex, there were no significant differences in baseline characteristics between moCEBPA and biCEBPA patient samples (Table 1).

Targeted sequencing analysis of these 42 genes revealed that moCEBPA patients had significantly more additional mutations than biCEBPA patients (mean: 4.0 ± 1.7 vs 2.2 ± 1.5 ; $P < .001$). The number of additional mutated genes was also significantly higher in moCEBPA patients than biCEBPA patients (mean: 3.7 ± 1.6 vs 2.0 ± 1.3 ; $P < .001$) (supplemental Figure 1). The 2 groups differed significantly with regard to mutations in the following genes: *NPM1*, *FLT3*-TKD1/2, *IDH2*, *STAG2*, and *GATA2* (supplemental Figure 2). Patients without any additional mutations were more frequently found in the biCEBPA group than in the moCEBPA cohort (6/48, 13% vs 1/32, 3%; $P = .23$; Figure 2).

Moreover, we identified 2 distinct genetic subgroups in biCEBPA patients based on comutated genes (Figure 2). biCEBPA patients with mutations in chromatin/DNA modifiers (C), cohesin complex (C), and splicing (S) genes were defined as $\text{biCEBPA}^{\text{CCSpos}}$ ($n = 25$). The $\text{biCEBPA}^{\text{CCSpos}}$ group is mainly defined by *TET2* (20/25), *DNMT3A* (7/25), and *WT1* (7/25) mutations. The other group, $\text{biCEBPA}^{\text{CCSneg}}$, includes biCEBPA patients with mutations in signaling factors only and/or *GATA2* and patients with no additional mutations in the 42 genes analyzed. In a cohort of 51 biCEBPA patients without recurrent chromosomal abnormalities and genomic rearrangements (analyzed in a large AML cohort of 1540 patients reported by the Cancer Genome Project), we also identified a $\text{biCEBPA}^{\text{CCSneg}}$ subgroup; however, this group is smaller (31%) than ours (48%) (supplemental Figure 3). The most frequently




Figure 4. Survival data depending on biogroup and *TET2* status.

(A) OS of biCEBPA^{CCSneg}, biCEBPA^{CCSpos}, and moCEBPA patients.

(B) OS of biCEBPA patients depending on *TET2* mutational status.

mutated gene in the biCEBPA^{CCSpos} group of the Cancer Genome Project was *WT1* (20%).²¹

biCEBPA^{CCSpos} patients were significantly older than biCEBPA^{CCSneg} patients (66 vs 48 years, $P = .005$; Figure 3A; Table 2). Patients in CCSpos subgroup also had a lower CR rate (Figure 3B) and a higher early death rate (supplemental Table 6).

biCEBPA^{CCSpos} patients had a trend to poorer outcome in terms of OS than biCEBPA^{CCSneg} patients (hazard ratio [HR], 2.6; 95% confidence interval [CI], 0.9-7.4; $P = .078$; Figure 4A). RFS and cumulative incidence of relapse were not statistically significant (supplemental Figure 4)

Multivariable Cox regression including CCS status and age suggested that age does not fully explain the potential differences in OS (adjusted CCS HR, 2.0; 95% CI, 0.7-6.0; $P = .22$; supplemental Table 5). In a multivariable logistic regression model

to assess the association between CR and CCS after adjusting for age, the score was prognostic for patients in CR (adjusted CCS OR, 0.17; 95% CI, 0.03-1.01; $P = .05$), but not patients in CR or CR with incomplete hematologic recovery (adjusted CCS OR, 0.58; 95% CI, 0.08-3.97; $P = .58$; supplemental Table 7). For the end point early death at day 60, the model proved to be unsuitable, because there was no early-death event in the biCEBPA^{CCSneg} cohort and only 4 in the biCEBPA^{CCSpos} cohort (supplemental Table 6). Accounting for a reduced statistical power due to small numbers, CCS status might have an independent influence on survival. Survival of biCEBPA^{CCSpos} and moCEBPA patients was comparable (Figure 4A).²⁸

biCEBPA^{CCSpos} and biCEBPA^{CCSneg} patients did not significantly differ in treatment regimens, which consisted of high-dose cytarabine and mitoxantrone vs 6-thioguanine, standard-dose cytarabine and daunorubicin (TAD9) (supplemental Table 8).

Figure 5. Mutational status of biCEBPA^{CCSpos} and biCEBPA^{CCSneg} remission samples (age is given in brackets).

(A) Four out of 5 biCEBPA^{CCSpos} patients had persisting clones in CR, indicating a clonal hematopoiesis. (B) None of the 5 biCEBPA^{CCSneg} samples had a detectable mutation load at the time of remission. Dx, diagnosis.

	biCEBPA CCSpos									
	UPN21 (60)		UPN43 (67)		UPN25 (75)		UPN69 (84)		UPN71 (76)	
	Dx	CR	Dx	CR	Dx	CR	Dx	CR	Dx	CR
CEBPA	+	-	+	-	+	-	+	-	+	-
TET2	+	+	+	+	+	+	+	+	+	-
DNMT3A	+	+	+	+	+	-				
WT1									+	-
SRSF2									+	-

	biCEBPA CCSneg									
	UPN24 (43)		UPN64 (46)		UPN65 (57)		UPN63 (41)		UPN18 (38)	
	Dx	CR	Dx	CR	Dx	CR	Dx	CR	Dx	CR
CEBPA	+	-	+	-	+	-	+	-	+	-
GATA2	+	-	+	-	+	-	+	-		
KRAS							+	-		
CSF3R									+	-

As most of the patients in biCEBPA^{CCSpos} group (20/25, 80%) were defined by *TET2* mutations, we further analyzed the prognostic effect of *TET2*. OS (HR, 3.1; 95% CI, 1.2-8.1; $P = .024$) was significantly worse in biCEBPA patients with a *TET2* mutation than those without a *TET2* mutation (Figure 4B). In biCEBPA patients, there was a trend for an effect of *TET2* on RFS (supplemental Figure 5).

We also analyzed OS and RFS in moCEBPA patients (supplemental Figure 6A-B). In 32 ($n = 14$ *TET2* mutated) and 21 ($n = 8$ *TET2* mutated) moCEBPA patients, there was no significant difference in OS (HR, 2.0; 95% CI, 0.8-5.2; $P = .15$) and RFS (HR, 0.9; 95% CI, 0.3-2.9; $P = .99$), respectively.

TET2 and *DNMT3A* mutations, which largely define our biCEBPA^{CCSpos} subgroup, are frequently present during complete morphologic remission as a result of clonal hematopoiesis.^{29,30} This finding leads us to the hypothesis that in some biCEBPA^{CCSpos} patients, a preleukemic clone might have been present (supplemental Figure 7). In 4 out of 5 patients for whom material from complete morphologic remission was available, we could identify persisting *TET2* or *DNMT3A* mutations (Figure 5A; supplemental Table 9). It is very likely that in these patients, the *TET2* and *DNMT3A* mutations might have preceded the *CEBPA* mutations. In contrast, we did not find persisting mutations in available remission samples ($n = 5$) from the biCEBPA^{CCSneg} subgroup (Figure 5B).

In 6% to 10% of biCEBPA-mutated AML patients, 1 of the *CEBPA* mutations is of germline origin.^{31,32} Because of younger age and fewer or no concomitant mutations, a germline *CEBPA* variant would be more likely to occur in biCEBPA^{CCSneg} patients.

Remission material was available from 8 out of 23 biCEBPA^{CCSneg} samples, and these patients had no persisting *CEBPA* mutation. In 7 out of 25 biCEBPA^{CCSpos} samples, we also did not detect a *CEBPA* germline mutation.

Discussion

Our study provides novel key findings with genetic relevance in *CEBPA*-mutated AML. We studied a cohort of 80 *CEBPA*-mutated CN-AML patients, including 48 patients with biallelic mutations. Samples from these patients were genetically well characterized by deep amplicon sequencing, with a special focus on mutation patterns between moCEBPA and biCEBPA patient samples and within the biCEBPA subgroup.

In this dataset, we identified novel associations of moCEBPA with *STAG2* and *FLT3-TKD1/2* mutations.^{2,23} Previously, Lavalley et al identified recurrent mutations (T618I) in the *CSF3R* (29%) gene in a small cohort of 14 patients with double-mutated *CEBPA*.¹⁴ *CSF3R* is the receptor for colony-stimulating factor 3 and, like *CEBPA*, is crucial for normal granulopoiesis.³³ In this cohort of biCEBPA patients, the mutation frequency of the T618I *CSF3R* was 10%. Because of the larger size of our biCEBPA cohort and the fact that we only included normal-karyotype-AML the mutation frequency of *CSF3R* in our cohort might be more representative of biCEBPA CN-AML patients.

We found a higher frequency of *TET2* mutations in moCEBPA (44%) and biCEBPA patients (42%) than in other AML or *CEBPA*-mutated AML cohorts (8% to 24%).²³⁻²⁵ When we compared these data with our wtCEBPA cohort data set, we found that *TET2*

mutations define a distinct subgroup of *CEBPA*-mutated samples regardless of allelic status. Most mutations result in a frame shift or premature stop codon, underscoring their functional relevance. The presence of a *TET2* mutation in bi*CEBPA* patients has a negative impact on OS, which is in concordance with the findings of Grossmann et al.³¹

We also could show that patients in the bi*CEBPA* subgroup had a significantly lower frequency of cooccurring mutations. Although we did not perform genome-wide analysis, these data suggest that the second hit in the *CEBPA* gene may drive leukemogenesis, and fewer cooperating mutations in other genes might therefore be required.

We identified 2 genetic subgroups in bi*CEBPA*-mutated AML and validated this finding in a bi*CEBPA* patient cohort from Papaemmanuil et al.²¹ Patients in the bi*CEBPA*^{CCSpos} group were significantly older and had a poorer prognosis, and most patients with remission samples available had persisting mutations in *TET2* and/or *DNMT3A*, suggesting preleukemic clonal hematopoiesis even before the onset of leukemia. These data suggest that CCS mutations are the initiating events in this subgroup, followed by the acquisition of bi*CEBPA* mutations. In contrast, bi*CEBPA*^{CCSneg} patients were younger, had a unique pattern of co-occurring mutations, cleared all mutations in remission, and had a favorable prognosis.

Two patients with mo*CEBPA* mutation also had persisting *DNMT3A* mutations. Due to a lack of samples, we could not perform any further analysis in this cohort.

The poorer prognosis, higher early death rate, and lower CR rate in bi*CEBPA*^{CCSpos} patients could only partly be explained by older age. Clonal hematopoiesis might also be a risk factor for early death, although our study lacks the statistical power to test this hypothesis. Recent data indicate that healthy individuals with clonal hematopoiesis of indeterminate potential have a higher risk of cardiovascular disease.³⁴ In a logistic regression model, the CCS score for bi*CEBPA*-mutated patient samples was prognostic for patients in CR.

In conclusion, our results suggest that bi*CEBPA* mutations can be further subdivided by CCS mutation status in 2 groups with distinct genetic characteristics. This subclassification provides

insight in the pathogenesis of the disease and might help to further refine prognostic classification of AML.

Acknowledgments

The authors thank Gudrun Mellert, Evelyn Packeiser, and Kathrin Bräundl (Ludwig-Maximilians-Universität) as well as Oliver Wachter (Center for Human Genetics and Laboratory Medicine, Martinsried, Germany) for excellent technical support. The authors acknowledge the contribution of all participants of the AMLCG trial and recruiting centers.

AMLCG clinical trials were supported by Deutsche Krebshilfe. This study was supported by the Deutsche Forschungsgemeinschaft (DFG SFB 1243, TPA07) (K.S.). S.K.B. is supported by Leukaemia & Blood Cancer New Zealand and the family of Marijanna Kumerich.

Authorship

Contribution: N.P.K., A.D., and K.S. designed the study; N.P.K., K.H.M., and M.R.-T. analyzed sequencing data; N.P.K., E.H., F.P., and T. Herold performed statistical analysis; N.P.K., S.K.B., S.S., B.K., S.T., and A.D. were involved in the laboratory characterization of patient samples; F.P. and M.C.S. provided clinical follow-up data. T. Hinrichsen and H.-G.K. performed sequencing on the Ion PGM system and analyzed the data; J.B., W.E.B., B.J.W., M.C.S., and W.H. coordinated the AMLCG clinical trial; K.S., J.B., W.H., S.K.B., and K.H.M. were involved in patient care; N.P.K., K.S., F.P., and T. Herold wrote the manuscript with help from all authors; K.S. supervised the project; and all authors had access to primary clinical trial data.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: T. Herold, 0000-0002-9615-9432; E.H., 0000-0002-0749-1389; S.K.B., 0000-0002-2202-9088; K.H.M., 0000-0003-3920-7490.

Correspondence: Karsten Spiekermann, Department of Internal Medicine III, University Hospital, LMU, Campus Grosshadern, Marchioninistr 15, 81377 Munich, Germany; e-mail: karsten.spiekermann@med.uni-muenchen.de.

References

1. Benthous T, Schneider F, Mellert G, et al. Rapid and sensitive screening for *CEBPA* mutations in acute myeloid leukaemia. *Br J Haematol*. 2008; 143(2):230-239.
2. Dufour A, Schneider F, Metzeler KH, et al. Acute myeloid leukemia with biallelic *CEBPA* gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. *J Clin Oncol*. 2010;28(4):570-577.
3. Fröhling S, Schlenk RF, Stolze I, et al. *CEBPA* mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. *J Clin Oncol*. 2004;22(4):624-633.
4. Gombart AF, Hofmann WK, Kawano S, et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. *Blood*. 2002;99(4):1332-1340.
5. Asou H, Gombart AF, Takeuchi S, et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. *Genes Chromosomes Cancer*. 2003;36(2):167-174.
6. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129(4):424-447.
7. Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of *CEBPA*, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. *Nat Genet*. 2001;27(3):263-270.

8. Schlenk RF, Döhner K, Krauter J, et al; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *N Engl J Med*. 2008;358(18):1909-1918.
9. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. *Blood*. 2009;113(13):3088-3091.
10. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127(20):2391-2405.
11. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. *J Clin Oncol*. 2010;28(16):2739-2747.
12. Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. *Blood*. 2011;117(8):2469-2475.
13. Greif PA, Dufour A, Konstandin NP, et al. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. *Blood*. 2012;120(2):395-403.
14. Lavallée VP, Kros J, Lemieux S, et al. Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors. *Blood*. 2016;127(24):3054-3061.
15. Büchner T, Berdel WE, Schoch C, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. *J Clin Oncol*. 2006;24(16):2480-2489.
16. Braess J, Spiekermann K, Staib P, et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantrone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. *Blood*. 2009;113(17):3903-3910.
17. Metzeler KH, Herold T, Rothenberg-Thurley M, et al; AMLCG Study Group. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. *Blood*. 2016;128(5):686-698.
18. Kiyoi H, Naoe T, Yokota S, et al; Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. *Leukemia*. 1997;11(9):1447-1452.
19. Pardanani A, Lasho TL, Laborde RR, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. *Leukemia*. 2013;27(9):1870-1873.
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Ser A Stat Soc*. 1995;57(1):289-300.
21. Papaemmanuil E, Döhner H, Campbell PJ. Genomic classification in acute myeloid leukemia. *N Engl J Med*. 2016;375(9):900-901.
22. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. *J Clin Oncol*. 1990;8(5):813-819.
23. Fasan A, Haeflrich C, Alpermann T, et al. The role of different genetic subtypes of CEBPA mutated AML. *Leukemia*. 2014;28(4):794-803.
24. Gaidzik VI, Paschka P, Späth D, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. *J Clin Oncol*. 2012;30(12):1350-1357.
25. Ley TJ, Miller C, Ding L, et al; Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med*. 2013;368(22):2059-2074.
26. Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. *J Clin Oncol*. 2011;29(10):1373-1381.
27. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. *Blood*. 2009;114(1):144-147.
28. Pastore F, Kling D, Hoster E, et al. Long-term follow-up of cytogenetically normal CEBPA-mutated AML. *J Hematol Oncol*. 2014;7(1):55.
29. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. *Nat Genet*. 2012;44(11):1179-1181.
30. Shlush LI, Zandi S, Mitchell A, et al; HALT Pan-Leukemia Gene Panel Consortium. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia [published correction appears in *Nature*. 2014;508(7496):420]. *Nature*. 2014;506(7488):328-333.
31. Grossmann V, Haeflrich C, Nadarajah N, et al. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76.8% of cases with TET2 and GATA2 alterations impacting prognosis. *Br J Haematol*. 2013;161(5):649-658.
32. Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. *J Clin Oncol*. 2008;26(31):5088-5093.
33. Fleischman AG, Maxson JE, Luty SB, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. *Blood*. 2013;122(22):3628-3631.
34. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *N Engl J Med*. 2017;377(2):111-121.